» Articles » PMID: 33067554

Left Ventricular Remodeling and Dysfunction in Primary Aldosteronism

Overview
Journal J Hum Hypertens
Date 2020 Oct 17
PMID 33067554
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Primary aldosteronism (PA) is a common cause of secondary hypertension and is associated with worse cardiovascular outcomes. The elevated aldosterone in PA leads to left ventricular (LV) remodeling and dysfunction. In recent decades, clinical studies have demonstrated worse LV remodeling including increased LV mass and cardiac fibrosis in patients with PA compared to patients with essential hypertension. Several mechanisms may explain the process of aldosterone-induced LV remodeling, including directly profibrotic and hypertrophic effects of aldosterone on myocardium, increased reactive oxygen species and profibrotic molecules, dysregulation of extracellular matrix metabolism, endothelium dysfunction and circulatory macrophages activation. LV remodeling causes LV diastolic and systolic dysfunction, which may consequently lead to clinical complications such as heart failure, atrial fibrillation, ischemic heart disease, and other vascular events. Adequate treatment with adrenalectomy or medical therapy can improve LV remodeling and dysfunction in PA patients. In this review, we discuss the mechanisms of aldosterone-induced LV remodeling and provide an up-to-date review of clinical research about LV remodeling-related heart structural changes, cardiac dysfunction, and their clinical impacts on patients with PA.

Citing Articles

Non-Hypertensive Effects of Aldosterone.

Ekman N, Grossman A, Nieckarz A, Jedrzejewski L, Wolf J, Dworakowska D Int J Mol Sci. 2025; 26(2).

PMID: 39859256 PMC: 11766190. DOI: 10.3390/ijms26020540.


Left ventricle remodeling by CMR in treated patients with primary aldosteronism and primary systemic arterial hypertension.

Reiser C, Assuncao Jr A, Araujo-Filho J, Dantas Jr R, Bortolotto L, Parga-Filho J PLoS One. 2024; 19(12):e0316140.

PMID: 39715283 PMC: 11666001. DOI: 10.1371/journal.pone.0316140.


The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients.

Lin N, Chen T, Wu X, Chang Y, Tsai C, Liao C Hypertens Res. 2024; 48(2):563-573.

PMID: 39690251 DOI: 10.1038/s41440-024-02030-w.


The effect of spironolactone in reducing the risk of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery: randomized single-blind placebo-controlled study.

Farzaneh A, Moradi M, Safarpoor G, Karamian A Gen Thorac Cardiovasc Surg. 2024; .

PMID: 39485613 DOI: 10.1007/s11748-024-02101-2.


Evaluating the effects of adrenalectomy and mineralocorticoid receptor antagonist on cardiac remodeling and diastolic function in patients with aldosterone-producing adenoma.

Chang Y, Wu X, Chen T, Chen U, Liao C, Lai T Hypertens Res. 2024; 48(2):529-539.

PMID: 39448809 DOI: 10.1038/s41440-024-01946-7.


References
1.
Rossi G . Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep. 2010; 12(5):342-8. DOI: 10.1007/s11906-010-0134-2. View

2.
Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R . Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008; 168(1):80-5. DOI: 10.1001/archinternmed.2007.33. View

3.
Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A . Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013; 98(12):4826-33. DOI: 10.1210/jc.2013-2805. View

4.
Wu V, Wang S, Chang C, Hu Y, Lin L, Lin Y . Long term outcome of Aldosteronism after target treatments. Sci Rep. 2016; 6:32103. PMC: 5009379. DOI: 10.1038/srep32103. View

5.
Chen Z, Huang K, Lee J, Lin L, Chen C, Chang Y . Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J Hypertens. 2017; 36(2):353-360. DOI: 10.1097/HJH.0000000000001534. View